Free fatty acids decrease circulating ghrelin concentrations in humans. 2006

Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
Department M (endocrinology and diabetes), Aarhus University Hospital, DK-8000 Aarhus C, Denmark. lars.christian.gormsen@ki.au.dk

OBJECTIVE Concentrations of the orexigenic peptide ghrelin is affected by a number of hormones, which also affect circulating levels of free fatty acids (FFAs). The present study was therefore designed to determine the direct effect of FFAs on circulating ghrelin. METHODS Eight lean, healthy men were examined for 8 h on four occasions using variable infusion rates (0, 3, 6 and 12 microl/kg per min) of intralipid to create different plasma FFA concentrations. Constant levels of insulin and GH were obtained by administration of acipimox (250 mg) and somatostatin (300 microg/h). At the end of each study day a hyperinsulinaemic-euglycaemic clamp was performed. RESULTS Four distinct levels of FFAs were obtained at the end of the lipid infusion period (FFA(LIPID): 0.03 +/- 0.00 vs: 0.49 +/- 0.04, 0.92 +/- 0.08 and 2.09 +/- 0.38 mmol/l; ANOVA P < 0.0001) and during hyperinsulinaemia (FFA(LIPID+INSULIN): 0.02 +/- 0.00 vs: 0.34 +/- 0.03, 0.68 +/- 0.09 and 1.78 +/- 0.32 mmol/l; ANOVA P < 0.0001). Whereas, somatostatin infusion alone reduced ghrelin concentration by approximately 67%, concomitant administration of increasing amounts of intralipid reduced circulating ghrelin by a further 14, 19 and 19% respectively (change in ghrelin: 0.52 +/- 0.05 vs: 0.62 +/- 0.06, 0.72 +/- 0.09 and 0.71 +/- 0.05 microg/l; ANOVA P = 0.04). No further reduction in ghrelin concentration was observed during hyperinsulinaemia. CONCLUSIONS FFA exposure between 0 and 1 mmol/l significantly suppresses ghrelin levels independent of ambient GH and insulin levels.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D005217 Fat Emulsions, Intravenous Emulsions of fats or lipids used primarily in parenteral feeding. Intravenous Fat Emulsion,Intravenous Lipid Emulsion,Lipid Emulsions, Intravenous,Emulsion, Intravenous Fat,Emulsion, Intravenous Lipid,Emulsions, Intravenous Fat,Emulsions, Intravenous Lipid,Fat Emulsion, Intravenous,Intravenous Fat Emulsions,Intravenous Lipid Emulsions,Lipid Emulsion, Intravenous
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
February 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
April 2013, Nature medicine,
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
June 2005, Current diabetes reports,
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
April 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
May 2004, Journal of endocrinological investigation,
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
August 2002, Clinical endocrinology,
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
January 2018, Cardiovascular & hematological agents in medicinal chemistry,
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
April 1971, Lancet (London, England),
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
September 2003, The Journal of clinical endocrinology and metabolism,
Lars C Gormsen, and Jakob Gjedsted, and Signe Gjedde, and Esben Thyssen Vestergaard, and Jens S Christiansen, and Jens Otto Jørgensen, and Søren Nielsen, and Niels Møller
June 2001, Journal of endocrinological investigation,
Copied contents to your clipboard!